Yuan yuan Zhang

Dr. Yuan yuan Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SZShuhui Zhuang
Shuhui Zhuang
LCLiudi Chang
Liudi Chang
XFXiaoxi Feng
Xiaoxi Feng
WHWeiwen Hu
Weiwen Hu
ZYZhaobo Yang
Zhaobo Yang
YZYuan yuan Zhang
Yuan yuan Zhang
Background: Primary cardiac lymphoma (PCL) is an exceedingly uncommon type of lymphoma that primarily affects the heart and/or pericardium, or manifests through cardiac symptoms due to myocardial infiltration. The infrequency of PCL, coupled with its non-specific clinical presentations, often complicates early diagnosis. This study aims to fill the existing gap in clinical knowledge regarding PCL by detailing a case of PCL and examining its clinical features, auxiliary examinations, treatment approaches, and prognostic outcomes, thereby facilitating early detection and enhancing patient care.Methods: A thorough search of the PubMed and Chinese National Knowledge Infrastructure (CNKI) database was performed using keywords “heart” and “lymphoma” or “primary cardiac lymphoma”. This search encompassed publications from January 1, 2014, to November 1, 2024.Results: The review included 121 cases. These cases usually present with atypical symptoms, mainly circulatory and respiratory, including chest tightness, dyspnea, and edema, along with occasional neurological and gastrointestinal symptoms. Echocardiography served as the primary diagnostic method in 92.6% of cases, while a definitive diagnosis was achieved through pathological examination in all cases (100%). Treatment strategies predominantly included surgical intervention (44.6%) and chemotherapy (76.0%). Although surgery did not have a significant effect on survival rates, chemotherapy proved to be critical in improving patient survival.Conclusions: PCL, which arises in the cardiac or pericardial areas, is generally associated with a poor prognosis. It is essential for clinicians to develop a greater awareness and understanding of the characteristics of PCL to enhance early diagnosis. The timely initiation of chemotherapy is vital for improving survival rates and the overall quality of life for patients with PCL.

15 August 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SZShuhui Zhuang
Shuhui Zhuang
ZYZhaobo Yang
Zhaobo Yang
ZCZhuangzhuang Cui
Zhuangzhuang Cui
YZYuan yuan Zhang
Yuan yuan Zhang
FCFengyuan Che
Fengyuan Che

26 November 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LCLiudi Chang
Liudi Chang
ZYZhaobo Yang
Zhaobo Yang
CYCuicui Yang
Cuicui Yang
YWYuxiao Wang
Yuxiao Wang
DLDan Li
Dan Li
YZYuan yuan Zhang
Yuan yuan Zhang
Background: Fluid overload-associated large B-cell lymphoma (FO-LBCL) is an exceptionally rare lymphoma characterized by predominant involvement of serous body cavities—such as the pleura, peritoneum, and pericardium—in the absence of a solid tumor mass. Its low incidence and nonspecific clinical presentation, which often includes symptoms like dyspnea due to effusion, contribute to diagnostic challenges in early stages. This study aims to address current gaps in the understanding of FO-LBCL by reporting two new cases and reviewing the clinical features, treatment regimens, and outcomes of 57 documented patients. Furthermore, through a detailed analysis of FO-LBCL characteristics, this work discusses relevant differential diagnoses and potential treatment strategies. Methods: A literature search of PubMed and Web of Science was performed using the following search queries: (1) “Fluid overload-associated large B-cell lymphoma” OR “FO-LBC”; (2) “Human herpesvirus 8-unrelated” AND “effusion lymphoma”; (3) “HHV8-unrelated” AND “effusion lymphoma”. Results: This study included a total of 57 patients. Fluid accumulation most commonly affected the pleural cavity (84.2%), followed by the pericardial (31.6%) and peritoneal (21.1%) cavities. The predominant clinical manifestation was dyspnea (55.8%). Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol. CD20 expression was the most significant favorable prognostic factor (P = 6×10-7). Other factors associated with improved survival included the absence of CD138 expression (P = 0.0009), age ≥ 65 years (P = 0.0015), LDH ≤ 500 U/L (P = 0.0064), the presence of pleural effusion (P = 0.0099), and CD79a expression (P = 0.0411). Treatment with rituximabcontaining chemotherapy regimens was also a significant favorable factor (P = 0.0036). Conclusions: FO-LBCL often presents with dyspnea caused by fluid effusion. Routine laboratory tests typically show no significant abnormalities, making timely pathological examination essential for a definitive diagnosis. Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.

9 December 2024 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
WHWeiwen Hu
Weiwen Hu
LZLanlan Zang
Lanlan Zang
XFXiaoxi Feng
Xiaoxi Feng
SZShuhui Zhuang
Shuhui Zhuang
LCLiudi Chang
Liudi Chang
YZYuan yuan Zhang
Yuan yuan Zhang

3 September 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XWXiaoran Wang
Xiaoran Wang
AZAili Zheng
Aili Zheng
JSJie Sun
Jie Sun
ZZZongfa Zhu
Zongfa Zhu
WSWeiying Sun
Weiying Sun
LZLanlan Zang
Lanlan Zang
Breast cancer is one of the most prevalent malignant tumors affecting women worldwide. Although early-stage breast cancer treatments often result in favorable outcomes, recurrence and metastasis remain significant clinical challenges. Recent advancements in molecular biology and genetics have greatly enhanced our understanding of breast cancer. Epigenetics has emerged as a critical factor in the initiation, progression, and metastasis of breast cancer. Epigenetics refers to heritable changes in gene expression caused by chemical modifications that do not alter the DNA sequence, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA (ncRNA) regulation. Currently, numerous epigenetic drugs have been utilized in the clinical treatment and research of breast cancer. This review examines the relationship between epigenetics and breast cancer to better understand its role in pathogenesis and potential for novel therapeutic strategies.